Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
We evaluated the relationship between antithrombotic effects and pharmacodynamic (PD) marker changes produced by the novel factor (F)Xa inhibitors darexaban (YM150) and rivaroxaban in a rabbit model of plaque disruption-induced arterial thrombosis. Animals were subjected to catheter-induced endothelial denudation via the femoral artery followed by a two-week high-cholesterol diet. Plaque disruption was induced by balloon angioplasty, and then stasis was achieved by ligation at the distal side of the injured segment. Darexaban and rivaroxaban were administered orally 1 hour (h) before and 9 h after plaque disruption, and their antithrombotic effects were evaluated 24 h after the initiation of ligation. Prothrombin time (PT), activated partial thromboplastin time (APTT), and plasma FXa activity were measured using blood samples collected before and 1h after administration. Darexaban and rivaroxaban significantly reduced thrombus formation. The thrombus weight obtained in the 30 mg/kg darexaban group was comparable to that in the 1 mg/kg rivaroxaban group (2.17 ± 0.63 and 3.23 ± 1.64 mg, respectively, vs. 8.01 ± 1.08 mg in the control group). Plasma FXa activity correlated with the antithrombotic effects of darexaban and rivaroxaban, while PT only correlated with those of darexaban. Our findings suggest that the degree of plasma FXa inhibition may be useful for predicting antithrombotic effects of darexaban and rivaroxaban in arterial thrombosis. PT may also be useful in evaluating antithrombotic effects of darexaban in particular.
Applied Pharmacology Research Laboratories, Ibaraki, Japan. toshiyuki.funatsu@astellas.com
Toshiyuki
T
Funatsu
Atsushi
A
Yamashita
Seiji
S
Kaku
Yoshiyuki
Y
Iwatsuki
Yujiro
Y
Asada
D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage*; D001381:Azepines / Q000008:administration & dosage; D001549:Benzamides / Q000008:administration & dosage; D004195:Disease Models, Animal; D065427:Factor Xa Inhibitors; D005263:Femoral Artery / Q000473:pathology; D008055:Lipids / Q000097:blood; D008297:Male; D009025:Morpholines / Q000008:administration & dosage; D058226:Plaque, Atherosclerotic / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D011517:Prothrombin Time; D011817:Rabbits; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*
D000925:Anticoagulants; D001381:Azepines; D001549:Benzamides; D065427:Factor Xa Inhibitors; D008055:Lipids; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban; C569750:darexaban